Key Takeaways
- • Isomorphic Labs, the AI drug discovery startup led by Demis Hassabis, raised $5 billion in Series C funding, with Greenoaks and Sequoia Capital leading and a16z and Alphabet participating, according to Axios.
- • Galvanize Therapeutics, a Redwood City, California-based developer of pulsed electric field ablation technologies for oncology and chronic disease, raised a $130 million Series D led by HealthQuest Capital.
- • Galvanize's round was joined by Olympus Innovation Ventures and Braidwell.
Summary
In a separate venture capital deal, Galvanize Therapeutics, a Redwood City, California-based developer of pulsed electric field ablation technologies for oncology and chronic disease, raised a $130 million Series D. HealthQuest Capital led the round, joined by Olympus Innovation Ventures and Braidwell.
The primary source summary covers these two financings under the Venture Capital heading. Additional details on the Leo Pharma IPO delay and Eli Lilly's acquisition activity referenced in the headline are not available in the source material provided.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.